US equities |
INTC $66.26 ▼-28.03% AMZN $240.52 ▼-1.34% MU $890.91 ▼-4.64% NVDA $206.44 ▼-3.38% GOOGL $282.75 ▼-0.38% SNDK $1,191.55 ▼-10.41% SPCX $138.39 ▼-3.82% AMD $513.77 ▼-9.30%
FinancialContent

IGC Pharma, Inc. Common Stock (NY:IGC)

0.1877 -0.0115 (-5.77%)
Delayed Quote Updated: 11:20 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
Via ACCESSWIRE
News headline image
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
Via ACCESSWIRE
News headline image
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
Via ACCESSWIRE
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Receives Two Awards in NIH’s AI PREPARE Challenge
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
Via ACCESSWIRE
News headline image
IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
IGC Pharma, Inc. (NYSE American: IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge),... 
Via PRLog
Topics Artificial Intelligence Intellectual Property Regulatory Compliance
News headline image
The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1’s Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer’s
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Advances IGC-AD1 Research to Potentially Deliver ‘Breakthrough Treatment’ in Alzheimer’s Disease
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
From IGC Pharma, Inc.
Via Business Wire
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property Regulatory Compliance
News headline image
IGC Announces Results of its 2024 Annual Stockholders Meeting
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Preclinical Research Evaluating New Molecule IGC-1C in Treatment of Alzheimer’s Disease
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) AI-Driven Approach Reveals ‘Promising Opportunity’ for IGC-1A to Be a Potential GLP-1 Agonist
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
From IGC Pharma
Via Business Wire
News headline image
IGC Stock Earnings: IGC Pharma Beats EPS, Misses Revenue for Q1 2025 ↗
IGC stock results show that IGC Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025. 
Via InvestorPlace
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2025 Financial, Operational Results Report
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In India, Highlights Important Milestones In Alzheimer's Research ↗
 
Via Benzinga
News headline image
IGC Pharma Reports First Quarter Fiscal 2025 Results
From IGC Pharma, Inc.
Via Business Wire
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Buy’ Recommendation in AGP’s Analyst Coverage Research Report
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
From IGC Pharma, Inc.
Via Business Wire
BioMedNewsBreaks — IGC Pharma Inc.’s (NYSE American: IGC) TGR-63 Demonstrates Blood-Brain Barrier Permeability in Preliminary Findings
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
From IGC Pharma, Inc.
Via Business Wire
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Positive Data from TGR-63 Preclinical Studies
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Financial Report for Fiscal Year
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
From IGC Pharma, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >